BR112013002940A2 - adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos - Google Patents

adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos

Info

Publication number
BR112013002940A2
BR112013002940A2 BR112013002940A BR112013002940A BR112013002940A2 BR 112013002940 A2 BR112013002940 A2 BR 112013002940A2 BR 112013002940 A BR112013002940 A BR 112013002940A BR 112013002940 A BR112013002940 A BR 112013002940A BR 112013002940 A2 BR112013002940 A2 BR 112013002940A2
Authority
BR
Brazil
Prior art keywords
adjuvants
presenting cells
antigen presenting
targeting
new vaccine
Prior art date
Application number
BR112013002940A
Other languages
English (en)
Portuguese (pt)
Inventor
Flamar Anne-Laure
Zurawski Gerard
F Banchereau Jacques
Original Assignee
Baylor Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Institute filed Critical Baylor Res Institute
Publication of BR112013002940A2 publication Critical patent/BR112013002940A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112013002940A 2010-08-13 2011-08-12 adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos BR112013002940A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37376310P 2010-08-13 2010-08-13
PCT/US2011/047633 WO2012021834A1 (en) 2010-08-13 2011-08-12 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Publications (1)

Publication Number Publication Date
BR112013002940A2 true BR112013002940A2 (pt) 2019-09-24

Family

ID=45564978

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002940A BR112013002940A2 (pt) 2010-08-13 2011-08-12 adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos

Country Status (14)

Country Link
US (1) US20120039916A1 (enExample)
EP (1) EP2603235A4 (enExample)
JP (1) JP2013535508A (enExample)
KR (1) KR20130108295A (enExample)
CN (1) CN103328005A (enExample)
AR (1) AR082686A1 (enExample)
AU (1) AU2011289234B2 (enExample)
BR (1) BR112013002940A2 (enExample)
CA (1) CA2807585A1 (enExample)
MX (1) MX2013001527A (enExample)
RU (1) RU2013110889A (enExample)
TW (1) TWI506035B (enExample)
WO (1) WO2012021834A1 (enExample)
ZA (1) ZA201301013B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
AU2008246368A1 (en) * 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
AR085633A1 (es) * 2011-03-08 2013-10-16 Baylor Res Inst Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
AR088220A1 (es) 2011-08-29 2014-05-21 Baylor Res Inst Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma
EP2822599A4 (en) * 2012-03-05 2015-12-23 Univ Duke VACCINE FORMULATION
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
CN105555303A (zh) 2013-06-28 2016-05-04 贝勒研究院 用于多发性硬化症的树突细胞asgpr靶向免疫治疗剂
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
CA2922937A1 (en) 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
WO2015112749A2 (en) * 2014-01-22 2015-07-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
JP2017525655A (ja) * 2014-06-02 2017-09-07 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ アレルギーおよび炎症性疾患を治療するための方法および組成物
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN104689313A (zh) * 2015-03-04 2015-06-10 中国科学院海洋研究所 大菱鲆cd83分子作为疫苗佐剂的应用
WO2016179034A2 (en) * 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
RU2761980C2 (ru) * 2015-11-10 2021-12-14 Йейл Юниверсити Композиции и способы лечения аутоиммунных заболеваний и рака
CA3008192A1 (en) * 2015-12-15 2017-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Immunogenic construct comprising an ebv-cell antigen and a targeting moiety and applications thereof
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
TWI805127B (zh) 2016-03-04 2023-06-11 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CN110769827A (zh) 2017-06-23 2020-02-07 博笛生物科技有限公司 药物组合物
EP3645043A4 (en) * 2017-06-28 2021-04-07 The Board of Trustees of the Leland Stanford Junior University METHODS AND COMPOSITIONS FOR DECTIN 2 STIMULATION AND CANCER IMMUNOTHERAPY
CA3083231A1 (en) * 2017-11-29 2019-06-06 Adaptive Phage Therapeutics, Inc. Methods of vaccination using icosahedral phage
JP7089596B2 (ja) * 2018-02-28 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体
WO2020154424A1 (en) * 2019-01-22 2020-07-30 The Brigham And Women's Hospital, Inc. Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN113811547B (zh) * 2019-03-27 2024-06-25 国家医疗保健研究所 具有cd40激活特性的重组蛋白
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
JP2023502712A (ja) * 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4149974A1 (en) 2020-05-13 2023-03-22 Institut National de la Santé et de la Recherche Médicale (INSERM) Recombinant proteins with ox40 activating properties
JP2023528017A (ja) 2020-05-26 2023-07-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
CN111850006B (zh) * 2020-07-27 2022-04-22 齐鲁工业大学 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用
CA3200878A1 (en) 2020-11-12 2022-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
KR20230121759A (ko) * 2020-11-18 2023-08-21 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-marco 항체 및 이의 용도
MX2023007610A (es) 2020-12-23 2023-07-12 Inst Nat Sante Rech Med Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno.
CA3209251A1 (en) 2021-01-29 2022-08-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2023081806A2 (en) * 2021-11-04 2023-05-11 The General Hospital Corporation Anti-mesothelin antibody reagents
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
EP4601682A1 (en) * 2022-10-13 2025-08-20 The Brigham & Women's Hospital, Inc. Methods and compositions for improving response to immunotherapy
KR102878250B1 (ko) * 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물
WO2024216189A1 (en) * 2023-04-13 2024-10-17 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057915C (zh) * 1994-09-19 2000-11-01 中国医学科学院医药生物技术研究所 免疫佐剂
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
NZ593450A (en) * 2007-02-02 2012-08-31 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells
CN101679949B (zh) * 2007-02-23 2015-08-19 贝勒研究院 通过dectin-1激活人抗原呈递细胞的治疗性应用
DK2224954T3 (en) * 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
NZ594540A (en) * 2008-07-16 2012-01-12 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef antigen to dendritic cells using antibodies
CA2754743C (en) * 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
DK3138854T3 (da) * 2009-03-10 2022-04-11 Baylor Res Institute Antistoffer mod CD40
PT2406286T (pt) * 2009-03-10 2016-08-19 Baylor Res Inst Anticorpos anti-cd40 e seus usos
US20110274653A1 (en) * 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells

Also Published As

Publication number Publication date
EP2603235A4 (en) 2014-04-09
AU2011289234A1 (en) 2013-02-21
TW201208696A (en) 2012-03-01
AR082686A1 (es) 2012-12-26
US20120039916A1 (en) 2012-02-16
JP2013535508A (ja) 2013-09-12
WO2012021834A1 (en) 2012-02-16
ZA201301013B (en) 2015-10-28
MX2013001527A (es) 2013-04-24
RU2013110889A (ru) 2014-09-20
AU2011289234B2 (en) 2014-09-11
CN103328005A (zh) 2013-09-25
KR20130108295A (ko) 2013-10-02
EP2603235A1 (en) 2013-06-19
CA2807585A1 (en) 2012-02-16
TWI506035B (zh) 2015-11-01

Similar Documents

Publication Publication Date Title
BR112013002940A2 (pt) adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
AR085633A1 (es) Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
MX363307B (es) Plataformas para suministro de antigenos.
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
AR091649A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EA201070329A1 (ru) Векторы и конструкции для доставки гриппозного антигена
CO6751288A2 (es) Composición antigénica de micobacteria
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
AR088513A1 (es) Inmunoenlazantes dirigidos contra esclerostina
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
JO3257B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
BRPI0510430A (pt) composições e métodos para vacinação mucosal
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112012028326A2 (pt) anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
CR20160570A (es) Anticuerpos anti-pld1 y su uso para mejorar la función de las celulas t
CL2014000786A1 (es) Composicion que comprende un péptido que se une de manera inmunoespecífica a la secuencia a relacionada con el polipeptido mhc de clase i (mica); método para obtener células inmunes dirigidas contra un antígeno propio de un individuo.
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
WO2009143457A3 (en) Vaccine composition containing synthetic adjuvant
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
DK2068918T3 (da) Vaccinesammensætning omfattende syntetisk adjuvant
PH12015501519A1 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
BRPI0520330A2 (pt) adjuvante a base de ácido polinosìnico-policitidìlico
BR112013031943A2 (pt) "proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos".

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.